Market News & Trends
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
Brooklyn ImmunoTherapeutics, Inc. recently announced 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by…
Proscia & Datavant Partner to Connect Pathology Data With Health Data Ecosystem for Life Sciences R&D
Proscia and Datavant recently announced a partnership that will provide life sciences companies with digitized pathology data to power the development of novel therapeutics and diagnostics.…
INCOG BioPharma Services Builds State-of-the-Art Facility With Promise to Deliver a Better Customer Experience
INCOG BioPharma Services is nearing completion on the construction of its manufacturing facility and global headquarters in Fishers, Indiana. The 90,000-sq-ft facility will be the…
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
HUTCHMED (China) Limited recently announced the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to HMPL-523,…
Zai Lab Announces First Patient Treated in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
Zai Lab Limited recently announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor Treating…
Catalent Increases Specialized Packaging Capabilities at its Philadelphia Facility to Support Growing Biologic & Cell & Gene Therapy Markets
Catalent recently announced it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and…
Definitive Agreement to Acquire Exelead Will Strengthen the CDMO Offering for mRNA of the Life Science Business of Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany recently announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO), for approximately…
SK Inc., the Second Largest Conglomerate in South Korea, Has Invested $350 Million in the Center for Breakthrough Medicines
The Center for Breakthrough Medicines recently announced it has received $350 million in equity financing from SK Inc.. CBM is partnering with SK to create…
Black Diamond Therapeutics Announces FDA Allowance of IND Application for a MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma & Non-Small Cell Lung Cancer
Black Diamond Therapeutics, Inc. recently announced the US FDA has cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535, an irreversible, mutant…
Harpoon Therapeutics Provides Pipeline Development Milestones for 2022
Harpoon Therapeutics, Inc. recently provided a pipeline milestone update on its TriTAC development programs. “We are excited to begin 2022 with a catalyst rich year…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….